Molecular Endocrinology, Vol 8, 886-894, Copyright © 1994 by Endocrine Society

ARTICLES

An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system

M Birnbaumer, S Gilbert and W Rosenthal
Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030.

The mutation of the type-2 vasopressin receptor (V2R) apparently responsible for X-linked congenital nephrogenic diabetes insipidus (CNDI) in the Q3 family consists of a T to C transition in codon 113, causing the change of Arg-113 to Trp. Arg-113 is located in the putative first extracellular loop of the V2R next to a frequently conserved Cys thought to interact via a disulfide bridge with a Cys of the second extracellular loop. The present study explored whether this mutation may account for the CNDI phenotype. The mutation was excised from the genomic DNA of a Q3 patient and introduced into the V2R cDNA, which was then placed into an expression plasmid and transfected into COS cells for transient expression and murine L cells for stable expression. Studies with L cells expressing similar levels of wild type and Q3 receptors showed that the mutant receptor has a 20-fold reduced affinity for arginine vasopressin (AVP) and stimulates adenylyl cyclase with an EC50 that is increased by a factor of about 60-fold. The same shift in the EC50 for adenylyl cyclase stimulation was obtained when deamino[8-D-Arg]vasopressin was substituted for AVP. Studies with COS cells revealed that at equal levels of transfected DNA, the mutant receptor is expressed at lower levels (about 20%) than the wild type receptor, indicating that the mutation hinders the transport of the receptor to the cell membrane.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				P. M. Conn, A. Ulloa-Aguirre, J. Ito, and J. A. Janovick G Protein-Coupled Receptor Trafficking in Health and Disease: Lessons Learned to Prepare for Therapeutic Mutant Rescue in Vivo Pharmacol. Rev., September 1, 2007; 59(3): 225 - 250. [Abstract] [Full Text] [PDF]

				S. R. Hawtin, J. Simms, M. Conner, Z. Lawson, R. A. Parslow, J. Trim, A. Sheppard, and M. Wheatley Charged Extracellular Residues, Conserved throughout a G-protein-coupled Receptor Family, Are Required for Ligand Binding, Receptor Activation, and Cell-surface Expression J. Biol. Chem., December 15, 2006; 281(50): 38478 - 38488. [Abstract] [Full Text] [PDF]

				B. J. Feldman, S. M. Rosenthal, G. A. Vargas, R. G. Fenwick, E. A. Huang, M. Matsuda-Abedini, R. H. Lustig, R. S. Mathias, A. A. Portale, W. L. Miller, et al. Nephrogenic Syndrome of Inappropriate Antidiuresis N. Engl. J. Med., May 5, 2005; 352(18): 1884 - 1890. [Abstract] [Full Text] [PDF]

				J. ANTUNES-RODRIGUES, M. DE CASTRO, L. L. K. ELIAS, M. M. VALENCA, and S. M. McCANN Neuroendocrine Control of Body Fluid Metabolism Physiol Rev, January 1, 2004; 84(1): 169 - 208. [Abstract] [Full Text] [PDF]

				Y.-X. Tao and D. L. Segaloff Functional Characterization of Melanocortin-4 Receptor Mutations Associated with Childhood Obesity Endocrinology, October 1, 2003; 144(10): 4544 - 4551. [Abstract] [Full Text] [PDF]

				R. Bouley, T.-X. Sun, M. Chenard, M. McLaughlin, M. McKee, H. Y. Lin, D. Brown, and D. A. Ausiello Functional role of the NPxxY motif in internalization of the type 2 vasopressin receptor in LLC-PK1 cells Am J Physiol Cell Physiol, October 1, 2003; 285(4): C750 - C762. [Abstract] [Full Text] [PDF]

				M. Birnbaumer The V2 vasopressin receptor mutations and fluid homeostasis Cardiovasc Res, August 15, 2001; 51(3): 409 - 415. [Abstract] [Full Text] [PDF]

				S. Inaba, H. Hatakeyama, N. Taniguchi, and I. Miyamori The Property of a Novel V2 Receptor Mutant in a Patient with Nephrogenic Diabetes Insipidus J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 381 - 385. [Abstract] [Full Text]

				E. ALBERTAZZI, D. ZANCHETTA, P. BARBIER, S. FARANDA, A. FRATTINI, P. VEZZONI, M. PROCACCIO, A. BETTINELLI, F. GUZZI, M. PARENTI, et al. Nephrogenic Diabetes Insipidus: Functional Analysis of New AVPR2Mutations Identified in Italian Families J. Am. Soc. Nephrol., June 1, 2000; 11(6): 1033 - 1043. [Abstract] [Full Text]

				K. Pasel, A. Schulz, K. Timmermann, K. Linnemann, M. Hoeltzenbein, J. Jääskeläinen, A. Grüters, G. Filler, and T. Schöneberg Functional Characterization of the Molecular Defects Causing Nephrogenic Diabetes Insipidus in Eight Families J. Clin. Endocrinol. Metab., April 1, 2000; 85(4): 1703 - 1710. [Abstract] [Full Text]

				B. D. Gaylinn, V. I. DeAlmeida, C. E. Lyons Jr., K. C. Wu, K. E. Mayo, and M. O. Thorner The Mutant Growth Hormone-Releasing Hormone (GHRH) Receptor of the Little Mouse Does Not Bind GHRH Endocrinology, November 1, 1999; 140(11): 5066 - 5074. [Abstract] [Full Text]

				R. S. Wildin and D. E. Cogdell Clinical Utility of Direct Mutation Testing for Congenital Nephrogenic Diabetes Insipidus in Families Pediatrics, March 1, 1999; 103(3): 632 - 639. [Abstract] [Full Text]

				G. Innamorati, H. Sadeghi, and M. Birnbaumer Transient Phosphorylation of the V1a Vasopressin Receptor J. Biol. Chem., March 20, 1998; 273(12): 7155 - 7161. [Abstract] [Full Text] [PDF]

				H. Sadeghi, G. L. Robertson, D. G. Bichet, G. Innamorati, and M. Birnbaumer Biochemical Basis of Partial Nephrogenic Diabetes Insipidus Phenotypes Mol. Endocrinol., November 1, 1997; 11(12): 1806 - 1813. [Abstract] [Full Text]

				H. M. Sadeghi, G. Innamorati, M. Dagarag, and M. Birnbaumer Palmitoylation of the V2 Vasopressin Receptor Mol. Pharmacol., July 1, 1997; 52(1): 21 - 29. [Abstract] [Full Text]

				H. M. Sadeghi, G. Innamorati, and M. Birnbaumer An X-Linked NDI Mutation Reveals a Requirement for Cell Surface V2R Expression Mol. Endocrinol., June 1, 1997; 11(6): 706 - 713. [Abstract] [Full Text]